Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Oxygen double bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514169000 - Cyclopentanohydrophenanthrene ring system DOAI

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514178000 Oxygen single bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system 272
Entries
DocumentTitleDate
2013002995717-Hydroxyprogesterone Ester-Containing Oral Compositions and Related Methods - The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier.01-31-2013
20090176753Betulinol derivatives as anti-cancer agents - The present invention relates to a method of treating cancer selected from the group of cancers consisting of prostate cancer, renal cancer, breast cancer, ovarian cancer, CNS cancer, melanoma, lung cancer, and bladder cancer. This method involves administering to a patient in need of such treatment a therapeutically effective amount of a betulinol derivative compound of Formula (I). Also disclosed are conjugated and immunoconjugated derivatives of the compound of Formula (I) as well as methods of making and using them.07-09-2009
20130090317PROPHYLACTIC AND POST-ACUTE USE OF PROGESTERONE IN CONJUNCTION WITH ITS ENANTIOMER FOR USE IN TREATMENT OF TRAUMATIC BRAIN INJURIES - Compositions and methods for treating traumatic brain injury (TBI) and mild traumatic brain injury (mTBI) using progesterone and ent-progesterone are described.04-11-2013
20130090316Nasal Delivery Mechanism for Prophylactic and Post-Acute Use of Progesterone and/or itsEnantiomer for Use in Treatment of Mild Traumatic Brain Injuries - Compositions and methods for treating traumatic brain injury (TBI) and mild traumatic brain injury (mTBI) using progesterone and ent-progesterone are described.04-11-2013
20130090315PROPHYLACTIC AND POST-ACUTE USE OF PROGESTERONE TO BETTER OUTCOMES ASSOCIATED WITH CONCUSSION - Compositions and methods for treating traumatic brain injury (TBI) and mild traumatic brain injury (mTBI) using progesterone and ent-progesterone are described.04-11-2013
200903060315alpha-ANDROSTANE-3,6,17-TRIONE (KNELLER'S TRIONE) AND METHODS OF USE THEREFOR - Disclosed are compounds such as 5α-androstane-3,6,17-trione, formulations comprising said compounds, and methods of use thereof to stimulate endogenous testosterone production and improve athletic performance and libido.12-10-2009
2009009344819-NOR-PROGESTERONE FOR CONTRACEPTION - The invention relates to compounds of the general formula (I)04-09-2009
20120115830ASSAY METHODS FOR THE DETERMINATION OF FKBPL EXPRESSION LEVEL IN THE CONTEXT OF BREAST CANCER - Disclosed are methods that employ FKBPL as a marker for a subject's sensitivity to endocrine therapies in the treatment of cancers, and as a predictive marker of cancer progression and disease free survival in relation to hormone responsive cancers.05-10-2012
20090221544METHODS FOR THE TREATMENT OF A TRAUMATIC CENTRAL NERVOUS SYSTEM INJURY VIA A TAPERED ADMINISTRATION PROTOCOL - The present invention provides methods for the treatment or the prevention of neuronal damage in the CNS. Specifically, the methods of the invention provide for the administration of a therapeutically effective amount of a progestin or progestin metabolite following a traumatic or ischemic injury to the CNS such that, prior to termination of administration of the progestin or progestin metabolite the administration is tapered to avoid withdrawal. The drug taper employed can involve a linear taper, an exponential taper, progressively dividing administered doses by 50%, or can be determined based on the treating physician's assessment of the patient's response to therapy. The tapered administration methods of the present invention may be used in combination with any therapeutic protocol or regimen for the administration of a therapeutically effective amount of a progestin or progestin metabolite to treat a traumatic or ischemic CNS injury.09-03-2009
20110144076PRETERM DELIVERY DIAGNOSTIC ASSAY - The present invention in one aspect relates generally to the identification, provision and use of a plurality of biomarkers to provide risk assessment of a woman for preterm delivery, and products and processes related thereto. In one aspect, a novel plurality of biomarkers as described herein is provided to determine a risk for preterm delivery. In one aspect are methods for determining a risk of preterm delivery in a subject. In another aspect are methods of predicting the likelihood of preterm delivery in a subject. In yet another aspect are methods for identifying subjects at risk of preterm delivery, and kits for use in the method In yet another aspect are nucleic acid arrays comprising nucleic acid probes that hybridize to preterm delivery marker genes.06-16-2011
20090258848BIOMARKERS FOR INFLAMMATORY BOWEL DISEASE - The present invention relates to methods of determining inflammatory bowel disease status in a subject. The invention further relates to kits for determining inflammatory bowel disease status in a subject. The invention further related to methods of identifying biomarker for determining inflammatory bowel disease status in a subject.10-15-2009
20100120735COMPOUND SHOWING ANTI-INFLAMMATORY ACTIVITY AND ANTIVIRAL ACTIVITY, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, A PROCESS FOR OBTAINING THE SAME AND USE OF THE SAME IN THE TREATMENT OF EPIDEMIC KERATOCONJUNCTIVITES AND HERPETIC STROMAL KERATIS - The present invention refers to a compound having anti-inflammatory and antiviral activity according to the following structural formula:05-13-2010
20100267684USE OF BIOLOGICAL SURFACTANT AS ANTI-INFLAMMATORY AGENT AND TISSUE PRESERVATIVE SOLUTION - The present invention relates to a use of a biological surfactant as an anti-inflammatory agent and a tissue preservative solution. More particularly, the present invention is directed to an anti-inflammatory agent and a tissue preservative solution comprising a biological surfactant which blocks a reaction of a proinflammatory factor with a receptor by emulsifying the proinflammatory factor.10-21-2010
20100120736Mineralocorticoid Receptor Antagonists - Compounds of the formula (I) are provided having a steroid skeleton and substitution characteristics in the A and B rings of the steroid skeleton effective for mineralocorticoid receptor antagonism, and rings C and D of the steroid skeleton having substituents thereon according to formula (I), wherein R05-13-2010
20120289491METHODS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM INJURY VIA A TAPERED ADMINISTRATION PROTOCOL - The present invention provides methods for the treatment or the prevention of neuronal damage in the CNS. Specifically, the methods of the invention provide for the administration of a therapeutically effective amount of a progestin or progestin metabolite following a traumatic or ischemic injury to the CNS such that, prior to termination of administration of the progestin or progestin metabolite the administration is tapered to avoid withdrawal. The drug taper employed can involve a linear taper, an exponential taper, progressively dividing administered doses by 50%, or can be determined based on the treating physician's assessment of the patient's response to therapy. The tapered administration methods of the present invention may be used in combination with any therapeutic protocol or regimen for the administration of a therapeutically effective amount of a progestin or progestin metabolite to treat a traumatic or ischemic CNS injury.11-15-2012
20100056488CORTICOSTEROID CONJUGATES AND USES THEREOF - The invention features corticosteroids conjugated to either a charged group or a bulky group in a manner that resists in vivo cleavage, the resulting conjugate is a peripherally acting steroid with reduced activity in the central nervous system. The invention provides a method for treating a patient having an inflammatory disease by administering to the patient a corticosteroid conjugate.03-04-2010
20080269178Pharmaceutical Manufacturing Process For Heat Sterilized Glucocorticoid Suspensions - The present invention provides a method for preparing a sterile suspension of a glucocorticosteroid. The glucocorticosteroids used in the invention are preferably antiinflammatory glucocorticosteroids. By making the last stage of product preparation be the sterilization process, the potential for contamination during manufacture and heat degradation of products is greatly reduced.10-30-2008
20090264395PROGESTERONE FOR THE TREATMENT OR PREVENTION OF SPONTANEOUS PRETERM BIRTH - A method for treating or preventing spontaneous preterm birth in pregnant women and improving neonatal morbidity and mortality. The method includes administering to a pregnant woman in need thereof an effective amount of progesterone sufficient to prolong gestation by minimizing the shortening or effacing of her cervix. Treatment and prophylaxis with progesterone in pregnant women having symptoms of short cervix has been clinically shown to increase neonatal health.10-22-2009
20090275543Modified Glycosaminoglycans, Pharmaceutical Compositions and Methods for Oral Delivery Thereof - This invention provides a composition comprising a depolymerized glycosaminoglycan or derivative thereof covalently linked to a bile acid. This invention also provides a pharmaceutical composition comprising a depolymerized glycosaminoglycan or derivative thereof covalently linked to a bile acid and a pharmaceutically acceptable carrier. Finally, this invention provides a method for orally delivering heparin to a subject comprising administering to the subject a pharmaceutically effective amount of a pharmaceutical composition comprising a glycosaminoglycan or derivative thereof covalently linked to a bile acid and (b) a pharmaceutically acceptable carrier.11-05-2009
20090186863USE OF CHOLEST-4-EN-3-ONE DERIVATIVES FOR OBTAINING A CYTOPROTECTIVE DRUG - The present invention relates to the use of cholest-4-en-3-one derivatives for obtaining a cytoprotective drug, with the exception of a neuroprotective drug.07-23-2009
20080318914METHODS FOR THE TREATMENT OF A TRAUMATIC CENTRAL NERVOUS SYSTEM INJURY - Methods of treating a subject with a traumatic central nervous system injury, more particularly, a traumatic brain injury, are provided. The methods comprise a therapy comprising a constant or a two-level dosing regime of progesterone. In one method, a subject in need thereof is administered at least one cycle of therapy, wherein the cycle of therapy comprises administering a therapeutically effective two-level intravenous dosing regime of progesterone. The two-level dosing regime comprises a first time period, wherein a higher hourly dose of progesterone is administered to the subject, followed by a second time period, wherein a lower hourly dose of progesterone is administered to the subject.12-25-2008
20090325920METHODS FOR THE TREATMENT OF A TRAUMATIC CENTRAL NERVOUS SYSTEM INJURY - Methods of treating a subject with a traumatic central nervous system injury, more particularly, a traumatic brain injury, are provided. The methods comprise a therapy comprising a constant or a two-level dosing regime of progesterone. In one method, a subject in need thereof is administered at least one cycle of therapy, wherein the cycle of therapy comprises administering a therapeutically effective two-level intravenous dosing regime of progesterone. The two-level dosing regime comprises a first time period, wherein a higher hourly dose of progesterone is administered to the subject, followed by a second time period, wherein a lower hourly dose of progesterone is administered to the subject.12-31-2009
20090023696USE OF C3-C10 17ALFA-ESTERS OF 9,11-DEHYDROCORTEXOLONE AS ANTI-GONADOTROPHIC AGENTS - The present invention relates to the use of C01-22-2009
20090197848Synthetic mimics of mammalian cell surface receptors: method and compositions - The present invention relates to new synthetic receptors. More particularly, the present invention relates to the use of the synthetic receptors for delivering a protein, peptide, drug, prodrug, lipid, nucleic acid, carbohydrate or small molecule into a target cell via receptor-mediated endocytosis. According to the invention, novel synthetic mimics of cell surface receptors have been designed and methods for use of the same are disclosed.08-06-2009
20090203661Betulinic acid, derivatives and analogs thereof and uses therefor - Provided herein provided herein are novel analogs and derivatives of betulinic acid. Also provided is a method for inhibiting an activity of one or more specificity protein (Sp) transcription factors cells associated with a neoplastic disease using betulinic acid, betulinic acid analog(s) and/or derivative(s) effective to decrease expression of a microRNA with concomitant increase in Sp suppressor gene expression. The betulinic acid analogs and derivatives also are effective in methods provided herein for inhibiting proliferation of cells associated with a neoplastic disease for treating a cancer or for reducing toxicity of a cancer therapy in a subject via administration of an analog or derivative of betulinic acid and, optionally, another anticancer drug.08-13-2009
20090209506AMINO DERIVATIVES OF BETA-HOMOANDROSTANES AND BETA-HETEROANDROSTANES - New aminoalkoxyimino derivatives at position 3 of substituted B-homoandrostanes and B-heteroandrostanes, processes for their preparation, and to pharmaceutical compositions containing them for the treatment of cardiovascular disorders, such as heart failure and hypertension. In particular compounds having the general formula (I) are described, where the radicals have the meanings described in detail in the application.08-20-2009
20100240631PHARMACEUTICAL COMPOSITION FOR THE SUBLINGUAL ADMINISTRATION OF PROGESTERONE, AND METHOD FOR ITS PREPARATION - A pharmaceutical composition is described for the sublingual administration of progesterone in the form of a rapidly-disintegrating tablet, which is capable of promoting a greater bioavailability of the progesterone; a method for preparing said pharmaceutical composition is also described.09-23-2010
20120142654PROGNOSTIC MARKER FOR MAMMA CARCINOMA - The invention provides an analytical method for the determination of the susceptibility of a human patient suffering from breast cancer to anti-cancer treatment by providing an analytical method for determining the genetic predisposition of a patient in respect of susceptibility, e.g. responsiveness, to anti-cancer treatment, especially treatment using at least one chemotherapeutical agent and/or at least one anti-hormonal agent on the basis of analysis of a genetic marker.06-07-2012
20090203662NOVEL DERIVATIVES OF CHOLEST-4-EN-3-ONE OXIME, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PREPARATION METHOD - The object of the invention is the use as a drug of a compound fitting formula I08-13-2009
20090069278Hormonally-timed dermatological preparations - This invention provides a dermatological preparation to improve skin cosmesis or conditioning by using different formulations in a sequence that suits the needs of the skin at different points of the hormonal cycle. In its simplest implementation, this would be a two-phase skin treatment, such as a cosmetic, lotion or soap whose formulation changes to balance the differing states of hydration and reactivity of the skin during the early and late phases of the cycle. The formulations would be made in a way to be easily identified and delivered conveniently for use at different times of a hormonal cycle. The preparation would be packaged to permit the convenient purchase and dispensing of the different formulations in a manner that could be easily sequenced with the hormonal cycle.03-12-2009
20110028443LIGANDS FOR NEMATODE NUCLEAR RECEPTORS AND USES THEREOF - An effective anti-nematode methodology entails contacting nematodes with a biologically effective amount of at least one compound according to formula I:02-03-2011
201100344295a-ANDROSTANE-3,6,17-TRIONE (KNELLER'S TRIONE) AND METHODS OF USE THEREFOR - Disclosed are compounds such as 5α-androstane-3,6,17-trione, formulations comprising said compounds, and methods of use thereof to stimulate endogenous testosterone production and improve athletic performance and libido.02-10-2011
20100144691Treatment of Female Fertility Conditions Through Modulation of the Autonomic Nervous System - Methods are provided for treating a subject for a fertility condition. In accordance with the subject methods, at least a portion of a subject's autonomic nervous system is modulated to increase the sympathetic activity/parasympathetic activity ratio in a manner that is effective to treat the subject for the condition. Embodiments of the subject invention include modulating a subject's autonomic nervous system using electrical energy and/or one or more pharmacological agents. The subject methods find use in the treatment of a variety of different fertility conditions. Also provided are kits for use in practicing the subject methods.06-10-2010
20120245133METHODS FOR THE TREATMENT OF A TRAUMATIC CENTRAL NERVOUS SYSTEM INJURY - Methods of treating a subject with a traumatic central nervous system injury, more particularly, a traumatic brain injury, are provided. The methods comprise a therapy comprising a constant or a two-level dosing regime of progesterone. In one method, a subject in need thereof is administered at least one cycle of therapy, wherein the cycle of therapy comprises administering a therapeutically effective two-level intravenous dosing regime of progesterone. The two-level dosing regime comprises a first time period, wherein a higher hourly dose of progesterone is administered to the subject, followed by a second time period, wherein a lower hourly dose of progesterone is administered to the subject.09-27-2012
20100004217TOPICAL STEROIDAL FORMULATIONS - The present invention relates to formulations of poorly water soluble pharmaceutical agents of Formula I and II. The present invention also relates to compositions containing compounds of Formula I or II, and glucocorticoids, and methods for reducing side effects from glucocorticoid treatment by co-administration of compounds of Formula I and II. The compositions herein are useful for the treatment of diabetes and obesity related diseases including metabolic syndrome.01-07-2010
20110098259PREGNANE STEROIDS AND THEIR USE IN THE TREATMENT OF CNS DISORDERS - Steroid compounds possessing a hydrogen donor in 3beta position, either in the form of a hydroxy- or a sulfate group, function as efficient blockers of the 3alpha-hydroxy-pregnan-steroid action and thus have utility as therapeutic substances for the prevention and/or treatment of steroid related CNS disorders. Treatment methods based on the administration of these substances are disclosed, and these substances either alone or in combination are also suggested for the manufacture of pharmaceuticals for the treatment of many specific steroid induced CNS disorders.04-28-2011
20110082127NEW INJECTABLE FORMULATIONS CONTAINING PROGESTERONE - The present invention relates to injectable progesterone formulations and processes for their preparation.04-07-2011
20100144690MEDICAMENTS AND METHODS FOR PROMOTING WOUND CONTRACTION - Provided are antagonists of FXR activity for use as medicament for the prevention, reduction or inhibition of scarring. This use may preferably be to prevent, reduce or inhibit scarring formed on healing of wounds. The invention also provides corresponding methods of treatment. Preferred antagonists of FXR activity include guggulsterone (Z); guggulsterone (E); a scalarane; 80-574; and a 5α-bile alcohol. In advantageous embodiments, up to 32 μM of the antagonist of FXR activity may be provided per linear cm of wound, or cm06-10-2010
20100286104AGENT FOR INHIBITING VISCERAL FAT ACCUMULATION - To reduce amounts of fat accumulated in abdominal cavity and to prevent or ameliorate visceral fat type obesity, considered to be a main factor of metabolic syndrome, the present invention provides an agent or a food or drink which contains a compound having a lophenol skeleton, or an organic solvent extract or a hot water extract of a Liliaceae plant, or a fraction thereof containing the compound as an active ingredient.11-11-2010
20100324006HORMONE DELIVERY SYSTEM AND METHOD - A hormone delivery system and method are provided for administering bio identical human hormones using a combination of modalities for the treatment of human physiological conditions.12-23-2010
20120302535PROGESTERONE TREATMENT FOR IMPROVING SLEEP QUALITY - Described herein are therapeutic methods using progesterone and progesterone analogs to improve sleep quality. The methods may be particularly useful to treat subject with perturbed sleep patterns, such as subjects who suffer from mid-sleep period awakenings.11-29-2012
20120157422MARKER - The invention provides a method for identifying whether a pregnant subject has an increased risk of preterm labour comprising measuring the progesterone concentration in a sample obtained from the subject, wherein a reduced progesterone concentration is indicative of an increased risk of preterm labour and delivery.06-21-2012
20120046260Methods and Devices for Delivery of Compositions to Conduits - The present invention comprises systems, methods and devices for the delivery of visualizable or treatment compositions or therapeutic agents comprising device elements for diagnosis and/or treatment of conduits. A delivery system comprising an introducer shaft having at least one exit port and at least one delivery catheter for placement of compositions into the conduit, such as a fallopian tube.02-23-2012
20110166115USE OF MIFEPRISTONE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS - The invention generally pertains to the discovery that agents capable of inhibiting the binding of cortisol to its receptor can be used in methods for treating patients diagnosed with Amyotrophic Lateral Sclerosis (ALS).07-07-2011
20120122827Novel derivatives of cholest-4-en-3-one oxime, pharmaceutical compositions containing them and preparation method - The object of the invention is the use as a drug of a compound fitting formula I05-17-2012
20120232046METHOD AND KIT FOR REDUCING THE SYMPTOMS OF PERIPHERAL VASCULAR DISEASE - A method for reducing the symptoms of peripheral vascular disease and for improving peripheral circulation wherein a progestin is administered to a subject in need thereof.09-13-2012
20080255076Steroid-Derived Pharmaceutical Compositions - The present invention relates to the use of specific steroid derivatives in the preparation of medicaments for the treatment or prevention and/or amelioration of disorders relating to pathological processes in lipid rafts.10-16-2008
20080227763Topical hormonal composition with systemic action - The present invention relates to the area of chemotherapy and more especially to the development of new galenic forms for application to the skin.09-18-2008
20110224181METHODS FOR THE TREATMENT OF A TRAUMATIC CENTRAL NERVOUS SYSTEM INJURY - Methods of treating a subject with a traumatic central nervous system injury, more particularly, a traumatic brain injury, are provided. The methods comprise a therapy comprising a constant or a two-level dosing regime of progesterone. In one method, a subject in need thereof is administered at least one cycle of therapy, wherein the cycle of therapy comprises administering a therapeutically effective two-level intravenous dosing regime of progesterone. The two-level dosing regime comprises a first time period, wherein a higher hourly dose of progesterone is administered to the subject, followed by a second time period, wherein a lower hourly dose of progesterone is administered to the subject.09-15-2011
20130137667LIGANDS FOR NEMATODE NUCLEAR RECEPTORS AND USES THEREOF - An effective anti-nematode methodology entails contacting nematodes with a biologically effective amount of at least one compound according to formula I:05-30-2013
20110312928Progesterone Containing Oral Dosage Forms and Related Methods - The present invention provides for progesterone containing pharmaceutical oral dosage forms and related methods. The oral dosage forms can each include an amount of progesterone as well as a pharmaceutically acceptable carrier. The oral dosage forms can be formulated to have at least one of the following characteristics: the oral dosage form produces an pregnane metabolite mean blood plasma level of less than about 1000 nmol/L; the oral dosage form produces an pregnane metabolites mean blood plasma level, after administration of single dose of progesterone composition, such that the ratio of pregnane metabolite level to parent progesterone level of less than 10:1; has a dissolution rate in vitro, when measure using a USP Type-1 dissolution apparatus in 900 mL of deionized water with 2.0% (w/v) of sodium lauryl sulfate at 100 rpm, such that the oral dosage form releases at least 10 wt % of the progesterone within the first 30 minutes and/or releases less than 45 wt % in the first 4 hours; and the oral dosage form produces a ratio of mean plasma progesterone AUC to the amount of progesterone administered of more than 1.5×10−6 hr/mL:1.12-22-2011
20110312927Progesterone Containing Oral Dosage Forms and Related Methods - The present invention provides for progesterone containing pharmaceutical oral dosage forms and related methods. The oral dosage forms can each include an amount of progesterone as well as a pharmaceutically acceptable carrier. The oral dosage forms can be formulated to have at least one of the following characteristics: the oral dosage form produces an pregnane metabolite mean blood plasma level of less than about 1000 nmol/L; the oral dosage form produces an pregnane metabolites mean blood plasma level, after administration of single dose of progesterone composition, such that the ratio of pregnane metabolite level to parent progesterone level of less than 10:1; has a dissolution rate in vitro, when measure using a USP Type-1 dissolution apparatus in 900 mL of deionized water with 2.0% (w/v) of sodium lauryl sulfate at 100 rpm, such that the oral dosage form releases at least 10 wt % of the progesterone within the first 30 minutes and/or releases less than 45 wt % in the first 4 hours; and the oral dosage form produces a ratio of mean plasma progesterone AUC to the amount of progesterone administered of more than 1.5×1012-22-2011
20130196963TOPICAL STEROIDAL FORMULATIONS - The present invention relates to formulations of poorly water soluble pharmaceutical agents of Formula I and II. The present invention also relates to compositions containing compounds of Formula I or II, and glucocorticoids, and methods for reducing side effects from glucocorticoid treatment by co-administration of compounds of Formula I and II. The compositions herein are useful for the treatment of diabetes and obesity related diseases including metabolic syndrome.08-01-2013
20130210788METHOD FOR POST COITAL CONTRACEPTION IN OVERWEIGHT OR OBESE FEMALE SUBJECTS USING ULIPRISTAL ACETATE - The invention provides a method for providing post coital contraception in a female subject, comprising providing the subject with a therapeutically effective amount of ulipristal acetate, wherein the female subject is overweight or obese.08-15-2013

Patent applications in class Oxygen double bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system

Patent applications in all subclasses Oxygen double bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system